The device industry claims FDA’s de novo draft guidance won’t accomplish what the agency set out to do: speed up the review of devices that aren’t a good fit for either the 510(k) or PMA programs.
While it may take a change in law to truly address the issue, industry groups are suggesting some tweaks to...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?